Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Basit Öğe Kaydı
dc.authorid0000-0002-8909-2102en_US
dc.authorscopusid56035868800en_US
dc.authorwosidK-1194-2018en_US
dc.contributor.authorRazavi-Shearer, Devin
dc.contributor.authorGamkrelidze, Ivane
dc.contributor.authorPan, Calvin
dc.contributor.authorJia, Jidong
dc.contributor.authorBerg, Thomas
dc.contributor.authorGray, Richard
dc.contributor.authorLim, Young-Suk
dc.contributor.authorChen, Chien-Jen
dc.contributor.authorOcama, Ponsiano
dc.contributor.authorMekonnen, Hailemichael
dc.contributor.authorAbbas, Zaigham
dc.contributor.authorAbdallah, Ayat
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorRazavi, Homie
dc.date.accessioned2023-07-28T12:04:58Z
dc.date.available2023-07-28T12:04:58Z
dc.date.issued2023en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infection as a public health threat by 2030; existing therapies and prophylaxis measures make such elimination feasible, even in the absence of a virological cure. We aimed to estimate the national, regional, and global prevalence of HBV in the general population and among children aged 5 years and younger, as well as the rates of diagnosis, treatment, prophylaxis, and the future burden globally. Methods In this modelling study, we used a Delphi process with data from literature reviews and interviews with country experts to quantify the prevalence, diagnosis, treatment, and prevention measures for HBV infection. The PRoGReSs Model, a dynamic Markov model, was used to estimate the country, regional, and global prevalence of HBV infection in 2022, and the effects of treatment and prevention on disease burden. The future incidence of morbidity and mortality in the absence of additional interventions was also estimated at the global level. Findings We developed models for 170 countries which resulted in an estimated global prevalence of HBV infection in 2022 of 3·2% (95% uncertainty interval 2·7–4·0), corresponding to 257·5 million (216·6–316·4) individuals positive for HBsAg. Of these individuals, 36·0 million were diagnosed, and only 6·8 million of the estimated 83·3 million eligible for treatment were on treatment. The prevalence among children aged 5 years or younger was estimated to be 0·7% (0·6–1·0), corresponding to 5·6 million (4·5–7·8) children with HBV infection. Based on the most recent data, 85% of infants received three-dose HBV vaccination before 1 year of age, 46% had received a timely birth dose of vaccine, and 14% received hepatitis B immunoglobulin along with the full vaccination regimen. 3% of mothers with a high HBV viral load received antiviral treatment to reduce mother-to-child transmission. Interpretation As 2030 approaches, the elimination targets remain out of reach for many countries under the current frameworks. Although prevention measures have had the most success, there is a need to increase these efforts and to increase diagnosis and treatment to work towards the elimination goals.en_US
dc.description.sponsorshipJohn C Martin Foundation, Gilead Sciences, and EndHep2030.en_US
dc.identifier.citationRazavi-Shearer, D., Gamkrelidze, I., Pan, C., Jia, J., Berg, T., Gray, R. ... Razavi, H. (2023). Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. The Lancet Gastroenterology and Hepatology, 8(10), pp. 879-907. https://doi.org/10.1016/S2468-1253(23)00197-8en_US
dc.identifier.doi10.1016/S2468-1253(23)00197-8en_US
dc.identifier.endpage907en_US
dc.identifier.issn2468-1253
dc.identifier.issue10en_US
dc.identifier.pmidPMID: 37517414en_US
dc.identifier.scopus2-s2.0-85169786860en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage879en_US
dc.identifier.urihttps://doi.org/10.1016/S2468-1253(23)00197-8
dc.identifier.urihttps://hdl.handle.net/20.500.13055/511
dc.identifier.volume8en_US
dc.identifier.wosWOS:001158110000001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expandeden_US
dc.institutionauthorÖrmeci, Necati
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofThe Lancet Gastroenterology and Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitis Ben_US
dc.subjectProphylaxisen_US
dc.subjectCascade of Careen_US
dc.titleGlobal prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling studyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022 a modelling study.pdf
Boyut:
2.78 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu